Sub-microgram dose formulations for dose ranging studies with long acting bronchodilators and their fixed dose combination using metered dose inhalers (MDIs) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
Tiotropium dose emission is influenced by the inhalation flow and the recommended two inhalations for each dose Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005
Delivered dose and fine particle dose of aclidinium bromide 200 µg via the Genuair® inhaler are independent of flow rate within the working range of the device Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
Differences between pharmacokinetics of ciclesonide-active principle and budesonide following repeated dose inhalations Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Improvement in the drug delivery of salmeterol/fluticasone via a novel breath actuatedpressurized metered dose inhaler with a dose counter Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019
Systemic exposure and lung bioavailability across two different dose strengths of CHF5993 a novel Triple pMDI Source: International Congress 2016 – Pulmonary drug delivery Year: 2016
Breaking microgram barrier to conduct dose ranging studies with long acting bronchodilators from a novel cosuspension metered dose inhaler product platform Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles Source: International Congress 2015 – Lung function: waiting to exhale... Year: 2015
Dose comparability of fluticasone (F) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma using dose step-down study design Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003
Objective measurement of inhalation profiles in patients using metered dose inhalers (MDIs) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Variability of budesonide (BUD) fine particle dose (FPD) delivered through two multiple dose dry powder inhalers (MDPI) Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Performance characteristics of a multi dose dry powder inhaler (MDPI) with respect to the use of different deaggregation systems Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Two-tone trainer maintains a slow inhalation rate when using a metered dose inhaler (MDI) Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005
Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003